NASDAQ · ENGN
enGene Therapeutics Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for ENGN has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Oct 2026 | $-0.48 | $-0.39 | $-0.55 | 3 |
| Jan 2027 | $-0.36 | $-0.33 | $-0.39 | 2 |
| Apr 2027 | $-0.37 | $-0.35 | $-0.39 | 2 |
| Jul 2027 | $-0.37 | $-0.37 | $-0.37 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
MarketBeat · RTTNews · Fintel- MarketBeat · Oct 16, 1:02 AM EDTenGene Highlights Surfactant-Enhanced Bladder Cancer Therapy Data and 2027 Update PathenGene (NASDAQ:ENGN) used a company webinar to outline preclinical findings for its investigational non-viral gene therapy, detalimogene voraplasmid, used with a polidocanol surfactant bladder rinse, while community urologists discussed the treatment burden facing patients with h
- RTTNews · Sep 8, 10:46 AM EDTEnGene Advances Detalimogene Toward BLA With LEGEND Data Update Planned For Q4 2026(RTTNews) – enGene Therapeutics Inc. (ENGN) reported third-quarter 2026 financial results and provided clinical and corporate updates, highlighting continued progress toward a potential Biologics License Application (BLA) filing for detalimogene in high-risk, BCG-unresponsive non
- RTTNews · Sep 8, 8:37 AM EDTEnGene Therapeutics Inc. Earnings At $32.50 Mln In Q3(RTTNews) – enGene Therapeutics Inc. (ENGN) released a profit for third quarter of $32.50 million
- MarketBeat · Aug 13, 11:07 AM EDTenGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer MarketenGene (NASDAQ:ENGN) outlined its view of the high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer, or NMIBC, market, citing market research that it believes supports a larger addressable patient population and greater use of treatment sequencing bef
- RTTNews · Jun 19, 5:09 AM EDTWeekly Buzz: SPRO, ABBV Get FDA Nod, NMRA Halts KOASTAL; ENGN Cuts Jobs; BIIB Acquires RayThera(RTTNews) – This week, the biotech sector saw FDA approvals, alongside study halts, layoffs, strategic collaborations, acquisitions, deal closures, and encouraging data readouts.
- RTTNews · Jun 16, 4:50 AM EDTEnGene Therapeutics Reports Wider Net Loss In Q2; Expects BLA Filing For Detalimogene In H2, 2026(RTTNews) – enGene Therapeutics, Inc. (ENGN), a clinical-stage biotechnology company, reported results for the second quarter that ended on April 30, 2026, reflecting a wider net loss compared to the prior year and provided an update on near-term clinical and regulatory milestone
- MarketBeat · May 8, 7:05 PM EDTenGene Bladder Cancer Data Shows Promise, but Durability Questions RemainenGene (NASDAQ:ENGN) reported preliminary data from the pivotal Cohort 1 of its ongoing Phase 2 LEGEND trial evaluating detalimogene voroplasmide, or detalimogene, in patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. On a company
- Fintel · Apr 13, 8:04 PM EDTWBB Securities Initiates Coverage of enGene Therapeutics (ENGN) with Buy RecommendationFintel reports that on April 13, 2026, WBB Securities initiated coverage of enGene Therapeutics (NasdaqCM:ENGN) with a Buy recommendation. Analyst Price Forecast Suggests 232.71% Upside
- Fintel · Nov 17, 1:29 AM ESTenGene Holdings (ENGN) Price Target Increased by 10.59% to 24.20The average one-year price target for enGene Holdings (NasdaqCM:ENGN) has been revised to $24.20 / share. This is an increase of 10.59% from the prior estimate of $21.88 dated November 7, 2025. The price target is an average of many targets provided by analyst
- Fintel · Nov 12, 7:06 PM ESTUBS Maintains enGene Holdings (ENGN) Neutral RecommendationFintel reports that on November 12, 2025, UBS maintained coverage of enGene Holdings (NasdaqCM:ENGN) with a Neutral recommendation. Analyst Price Forecast Suggests 152.99% Upside
- Fintel · Nov 12, 7:06 PM ESTCitizens Maintains enGene Holdings (ENGN) Market Outperform RecommendationFintel reports that on November 12, 2025, Citizens maintained coverage of enGene Holdings (NasdaqCM:ENGN) with a Market Outperform recommendation. Analyst Price Forecast Suggests 152.99% Upside
- Fintel · Nov 12, 7:04 PM ESTMorgan Stanley Maintains enGene Holdings (ENGN) Overweight RecommendationFintel reports that on November 12, 2025, Morgan Stanley maintained coverage of enGene Holdings (NasdaqCM:ENGN) with a Overweight recommendation. Analyst Price Forecast Suggests 152.99% Upside
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for enGene Therapeutics Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.